MedTrace Logo

Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

NCT00304694 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2006-03-20

No results posted yet for this study

Summary

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.

We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

Conditions

  • Nasopharyngeal Cancer

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ruoh-Fang Yen, MD, PhD · National Taiwan University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • Taiwan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304694 on ClinicalTrials.gov